Cell One and CBM partner for cell and gene therapies
10 Mar 2023
Gene Therapy
Preview
Source: Pharmaceutical Technology
The collaboration allows cell and gene therapy asset owners to have access to end-to-end services to support research and development. Credit: Braňo / Unsplash.
Preview
Source: Pharmaceutical Technology
Cell One Partners has announced a strategic collaboration with the Center for Breakthrough Medicines (CBM) to expedite the development and commercialisation of cell and gene therapies.
Cell One Partners offers virtual company creation and management to its clients for complete aspects of the development and commercialisation of drugs.
The collaboration combines the virtual executive leadership and programme management of Cell One Partners with the technologies, capabilities, and capacity of CBM for the development, testing, and manufacturing of therapies.
The virtual company creation of Cell One Partners helps in removing the barriers to access to senior C-suite leadership by providing virtual management at one-third of the cost of a traditional new start-up company.
This allows the asset owners to focus their cash and energies on research and development.
With the collaboration with CBM, the cell and gene therapy asset owners will get access to end-to-end services for supporting process development, research and development, and clinical and commercial manufacturing, including starting materials along with cell banking.
Cell One Partners founder and CEO George Goldberger said: “Our unique model of creating and managing virtual companies for CGT asset owners allows them to accelerate their pathway to commercialization via our unparalleled network of cell and gene therapy leaders and innovators to support all aspects of the development, manufacturing, and commercialisation continuum at about one-third of the management cost of setting up a traditional company with C-level executives.
“The Center for Breakthrough Medicines is a valuable asset to our clients as their integrated, end-to-end services, all located in a single complex, allow innovator companies to optimise their working capital and focus on driving the science toward commercialisation.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free Whitepaper
Optimise your cell therapy process: a guide to cell thawing
Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer.
This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
Preview
Source: Pharmaceutical Technology
-->
By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy
By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.
Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.